4.5 Review

Fingolimod for Multiple Sclerosis: Mechanism of Action, Clinical Outcomes, and Future Directions

期刊

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
卷 11, 期 5, 页码 492-497

出版社

SPRINGER
DOI: 10.1007/s11910-011-0216-9

关键词

Multiple sclerosis; MS; Therapy; Fingolimod; FTY720; T cell; TRANSFORMS; FREEDOMS

资金

  1. Actelion
  2. Advancell
  3. Allozyne
  4. BaroFold
  5. Bayer Health Care Pharmaceuticals
  6. Bayer Schering Pharma
  7. Bayhill
  8. Biogen Idec
  9. BioMarin
  10. CLC Behring
  11. Elan
  12. Genmab
  13. GeNeuro SA
  14. Genmark
  15. GlaxoSmithKline
  16. Eli Lilly
  17. Merck Serono
  18. MediciNova
  19. Novartis
  20. Novonordisk
  21. Pepimmune
  22. Sanofi-Aventis
  23. Santhera
  24. Roche
  25. Teva
  26. UCB
  27. Wyeth
  28. Swiss MS Society
  29. Swiss National Research Foundation
  30. European Union
  31. Gianni Rubatto
  32. Roche Research Foundations
  33. Bayer Schering

向作者/读者索取更多资源

The oral sphingosine 1-phosphate receptor (S1PR) modulator fingolimod functionally antagonizes S1PR hereby blocking lymphocyte egress from secondary lymphoid organs to the peripheral blood circulation. This results in a reduction in peripheral lymphocyte counts, including potentially encephalitogenic T cells. In patients with relapsing multiple sclerosis fingolimod has been shown to be an effective treatment. In phase 2 and phase 3 studies fingolimod-treated patients had reduced disease activity clinically and in MRI. Although severe infectious complications occurred in single cases treated with fingolimod, the frequency of overall infections was comparable in fingolimod-treated patients and controls. Overall, in clinical studies fingolimod was well tolerated and had a favorable safety profile. In follow-up studies with continuous fingolimod, treatment showed sustained efficacy while being well tolerated.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据